Osome-positive acute lymphoblastic leukemia: Impact of tyrosine kinase inhibitors on treatment
Osome-positive acute lymphoblastic leukemia: Impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant 2012, 18(4):584?92. 10. Stock W, Prestidge T, Camitta B: Current treatment options for adults patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma 2010, 51(2):188?98.Farnsworth et al. Experimental Hematology Oncology 2012, 1:29 http://www.ehoonline.org/content/1/1/Page 5 of11. Ravandi F: Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk 2011, 3(6):731?42. 12. Merante SP, Colombo AA, Calatroni S, et al: Nilotinib restores long-term full-donor chimerism in ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation. Bone Marrow Transplantation 2009, 44:263?64. doi:10.1038/bmt.2009.6. 13. Tiribelli M, Spetotto A, Candoni A, et al: Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (ph all) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res 2009, 33(1):174?77. 14. Kang BW, Moon JH, Chae YS, et al: Pre-emptive treatment with nilotinib PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26024392 after second allogeneic transplantation in a Philadelphia chromosomepositive acute lymphoblastic leukemia patient with high risk of relapse. Acta Haematol 2010, 123:242?47. 15. Greinix H, van Besien K, Elmaagacli A: Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24 week course of extracorporeal photophoresis- results of a crossover randomized study. Biology of Blood and Marrow Transplantation 2011, 17(12):1775?782. 16. Flowers M, Apperley J, van Besien K, et al: A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008, 112(7):2667?774. 17. Chiesa-Fuxench Z, Gonzalez-Chavez J: Extracorporeal photopheresis: a review on the immunological aspects and clinical applications. P R Health Sci J 2010, 29(4):337?47. 18. Marshall S: Technology insight: Ecp for the treatment of gvhd an we offer selective immune control without generalized immunosuppression? Nat Clin Pract Oncol 2006, 3(6):302?14. 19. Goussetis E, Varela I, Tsirigotis P: Update on the mechanism of action and on clinical alpha-AmanitinMedChemExpress ��-Amatoxin efficacy of extracorporeal photopheresis in the treatment of acute and chronic graft versus host disease in children. Transfus Apher Sci 2012, 46(2):203?09. 20. Capitini C, Davis J, Larabee S: Update on the mechanism of action and on clinical efficacy of extracorporeal photopheresis in the treatment of acute and chronic graft versus host disease in children. Biol Blood Marrow Transplant 2011, 17(6):790?99.doi:10.1186/2162-3619-1-29 Cite this article as: Farnsworth et al.: Persistent complete molecular remission after nilotinib and graft-versus-leukemia effect in an acute lymphoblastic leukemia patient with cytogenetic relapse after allogeneic stem cell transplantation. Experimental Hematology Oncology 2012 1:29.Submit your next manuscript to BioMed Central and take full advantage of:?Convenient online submission ?Thorough peer review ?No space constraints or color figure charges ?Immediate publication on acceptance ?Inclusion in PubMed, CAS, Scopus and Google Scholar ?Research which is freely available for redistributionSubmit your manuscript at www.biomedcentral.com/submit
BMC GenomicsResearch articleBioMed CentralOpen AccessIn si.